logo

For the Inventor, By the Inventor

Abingdon, United Kingdom

Immunocore Limited

USPTO Granted Patents = 48

% Expired Patents = 10.4



Trademarks = 15

Forward Citations = 408

Loading Chart...
Loading Chart...

78 inventors (with patents filed for the assignee):

goldMedal Bent Karsten Jakobsen (26 out of 32 patents)

silverMedal Yi Li (14 out of 24 patents)

bronzeMedal Peter Eamon Molloy (12 out of 17 patents)

4.  Nathaniel Ross Liddy (11 out of 11 patents)

5.  Annelise Brigitte Vuidepot (8 out of 8 patents)

6.  Jonathan Michael Boulter (6 out of 9 patents)

7.  Steven Mark Dunn (6 out of 9 patents)

8.  Chandramouli Reddy Chillakuri (5 out of 5 patents)

9.  Stephen Harper (5 out of 5 patents)

10.  Tara Mahon (5 out of 6 patents)

11.  Alex Powlesland (4 out of 4 patents)

12.  Philip William Addis (4 out of 4 patents)

13.  Dhaval Jaykant Sangani (3 out of 3 patents)

14.  Graham Anthony Hood (3 out of 3 patents)

15.  Lucy Boulter, Legal Representative (3 out of 3 patents)


Core Competencies:
CD1a Antagonist
PD-1 Agonist
HBV Envelope Protein
HIV Binding Molecules
TCR Libraries
Bifunctional Polypeptides
Modified T Cell Receptors
High Affinity TCRs
MHC Complexes
Peptide Binding
T Cell Receptor Display
TCR Mutants

48 patents:

1. 12735491 - MULTI-DOMAIN CD1a ANTAGONIST/PD-1 AGONIST ANTIBODY MOLECULES (2026-09-15),
2. 12630610 - BINDING MOLECULES SPECIFIC FOR HBV ENVELOPE PROTEIN (2026-05-19),
3. 12590152 - CD3-SPECIFIC BINDING MOLECULES (2026-03-31),
4. 12195534 - Binding molecules (2025-01-14),
5. 12134647 - Binding molecules (2024-11-05),
6. 12103971 - HIV specific binding molecules (2024-10-01),
7. 12065475 - T cell receptors and fusion proteins thereof (2024-08-20),
8. 12018062 - T cell receptors (2024-06-25),
9. 11929151 - Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex (2024-03-12),
10. 11827688 - Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein (2023-11-28),
11. 11739442 - TCR libraries (2023-08-29),
12. 11739441 - TCR libraries (2023-08-29),
13. 11718657 - T cell receptors (2023-08-08),
14. 11639374 - T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex (2023-05-02),
15. 11505590 - T cell receptors (2022-11-22),
Company Overview
Immunocore Limited, headquartered in Abingdon, UK, specializes in the development of innovative therapies leveraging T cell receptor technology. The company focuses on creating binding molecules and high-affinity T cell receptors that target specific antigens, including those associated with HIV. Its research encompasses TCR libraries and bifunctional polypeptides, aiming to enhance immune responses against various diseases. Immunocore's advancements in modified T cell receptors position it at the forefront of immunotherapy and precision medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Immunocore Limited USPTO Patent Assignee Logo
48 Patents

#6 in Abingdon

#372 in United Kingdom

#14,561 in the World

Abingdon, GB
Abingdon, United Kingdom

Immunocore Limited

Forward Citations = 408

78 inventors:

goldMedal Bent Karsten Jakobsen (26 out of 32 patents)

silverMedal Yi Li (14 out of 24 patents)

bronzeMedal Peter Eamon Molloy (12 out of 17 patents)

4.  Nathaniel Ross Liddy (11 out of 11 patents)

5.  Annelise Brigitte Vuidepot (8 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immunocore Limited. Retrieved from https://idiyas.com/company/immunocore

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…